ASH 2023 | A CD38-targeting bispecific antibody in the treatment of R/R T-ALL
Guru Subramanian Guru Murthy, MD, Medical College of Wisconsin, Milwaukee, WI, discusses a Phase I dose-escalation trial (NCT05038644) investigating XmAb18968, a CD38-targeting bispecific antibody, in the treatment of relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL). Seven patients have been enrolled so far, and the agent has shown good tolerability and preliminary efficacy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Amgen; Honoraria: Cardinal Health, BeiGene, Kite, Pfizer; Advisory board: Cardinal Health, BeiGene, Kite, Pfizer; Speakers Bureau: Rigel
